These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

357 related items for PubMed ID: 31537897

  • 1. V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma.
    Muller S, Victoria Lai W, Adusumilli PS, Desmeules P, Frosina D, Jungbluth A, Ni A, Eguchi T, Travis WD, Ladanyi M, Zauderer MG, Sauter JL.
    Mod Pathol; 2020 Feb; 33(2):303-311. PubMed ID: 31537897
    [Abstract] [Full Text] [Related]

  • 2. Expression of V-set immunoregulatory receptor in malignant mesothelioma.
    Chung YS, Kim M, Cha YJ, Kim KA, Shim HS.
    Mod Pathol; 2020 Feb; 33(2):263-270. PubMed ID: 31363159
    [Abstract] [Full Text] [Related]

  • 3. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C, Galateau-Sallé F, McLeer-Florin A, Le Stang N, David-Boudet L, Duruisseaux M, Ferretti GR, Brambilla E, Lebecque S, Lantuejoul S.
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [Abstract] [Full Text] [Related]

  • 4. Shorter Survival in Malignant Pleural Mesothelioma Patients With High PD-L1 Expression Associated With Sarcomatoid or Biphasic Histology Subtype: A Series of 214 Cases From the Bio-MAPS Cohort.
    Brosseau S, Danel C, Scherpereel A, Mazières J, Lantuejoul S, Margery J, Greillier L, Audigier-Valette C, Gounant V, Antoine M, Moro-Sibilot D, Rouquette I, Molinier O, Corre R, Monnet I, Langlais A, Morin F, Bergot E, Zalcman G, Levallet G.
    Clin Lung Cancer; 2019 Sep; 20(5):e564-e575. PubMed ID: 31279641
    [Abstract] [Full Text] [Related]

  • 5. Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time.
    Pasello G, Zago G, Lunardi F, Urso L, Kern I, Vlacic G, Grosso F, Mencoboni M, Ceresoli GL, Schiavon M, Pezzuto F, Pavan A, Vuljan SE, Del Bianco P, Conte P, Rea F, Calabrese F.
    Ann Oncol; 2018 May 01; 29(5):1258-1265. PubMed ID: 29514216
    [Abstract] [Full Text] [Related]

  • 6. Expression of ALCAM (CD166) and PD-L1 (CD274) independently predicts shorter survival in malignant pleural mesothelioma.
    Inaguma S, Lasota J, Wang Z, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Ikeda H, Schrump DS, Hassan R, Miettinen M.
    Hum Pathol; 2018 Jan 01; 71():1-7. PubMed ID: 28811252
    [Abstract] [Full Text] [Related]

  • 7. Thoracic mesenchymal malignant tumors and programed cell death ligand-1 status: Clinicopathologic and prognostic analysis of eight pulmonary sarcomatoid carcinomas and eight malignant mesotheliomas.
    Otsubo K, Sakai H, Kimura H, Miyazawa T, Marushima H, Kojima K, Furuya N, Mineshita M, Chosokabe M, Koike J, Saji H.
    Thorac Cancer; 2021 Dec 01; 12(23):3169-3176. PubMed ID: 34655161
    [Abstract] [Full Text] [Related]

  • 8. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
    Forest F, Patoir A, Dal Col P, Sulaiman A, Camy F, Laville D, Bayle-Bleuez S, Fournel P, Habougit C.
    Pathology; 2018 Oct 01; 50(6):635-641. PubMed ID: 30145072
    [Abstract] [Full Text] [Related]

  • 9. The potential utility of GATA binding protein 3 for diagnosis of malignant pleural mesotheliomas.
    Prabhakaran S, Hocking A, Kim C, Hussey M, Klebe S.
    Hum Pathol; 2020 Nov 01; 105():1-8. PubMed ID: 32888937
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Higher concordance of PD-L1 expression between biopsies and effusions in epithelioid than in nonepithelioid pleural mesothelioma.
    Mansour MSI, Seidal T, Mager U, Dobra K, Brunnström H, Dejmek A.
    Cancer Cytopathol; 2021 Jun 01; 129(6):468-478. PubMed ID: 33493383
    [Abstract] [Full Text] [Related]

  • 12. PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma.
    Nguyen BH, Montgomery R, Fadia M, Wang J, Ali S.
    Asia Pac J Clin Oncol; 2018 Feb 01; 14(1):69-73. PubMed ID: 29105302
    [Abstract] [Full Text] [Related]

  • 13. Analysis of expression of programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).
    Cedrés S, Ponce-Aix S, Zugazagoitia J, Sansano I, Enguita A, Navarro-Mendivil A, Martinez-Marti A, Martinez P, Felip E.
    PLoS One; 2015 Feb 01; 10(3):e0121071. PubMed ID: 25774992
    [Abstract] [Full Text] [Related]

  • 14. The Immune Microenvironment, Genome-wide Copy Number Aberrations, and Survival in Mesothelioma.
    Thapa B, Salcedo A, Lin X, Walkiewicz M, Murone C, Ameratunga M, Asadi K, Deb S, Barnett SA, Knight S, Mitchell P, Watkins DN, Boutros PC, John T.
    J Thorac Oncol; 2017 May 01; 12(5):850-859. PubMed ID: 28257959
    [Abstract] [Full Text] [Related]

  • 15. CD70 and PD-L1 (CD274) co-expression predicts poor clinical outcomes in patients with pleural mesothelioma.
    Inaguma S, Ueki A, Lasota J, Komura M, Sheema AN, Czapiewski P, Langfort R, Rys J, Szpor J, Waloszczyk P, Okoń K, Biernat W, Schrump DS, Hassan R, Miettinen M, Takahashi S.
    J Pathol Clin Res; 2023 May 01; 9(3):195-207. PubMed ID: 36754859
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Programmed cell death 1 ligand 1 (PD-L1) expression is associated with poor prognosis of malignant pleural mesothelioma patients with good performance status.
    Rrapaj E, Giacometti L, Spina P, Salvo M, Baselli GA, Veggiani C, Rena O, Trisolini E, Boldorini RL.
    Pathology; 2021 Jun 01; 53(4):462-469. PubMed ID: 33272690
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.